Priothera
  • Home
  • Science
    • Mocravimod
    • Acute Myeloid Leukemia & Hematopoietic Cell Transplantation
    • CAR T Cells
    • Our Pipeline
    • Publications
  • MO-TRANS
  • Press
  • About
    • Our Leadership Team
    • Advisory Board
    • Investors
    • Our Partners
    • ESG and Recognition
  • Contact
Select Page

A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of KRP203 in subjects with hematological malignancies undergoing allogeneic hematopoietic cell transplantation

by admin | Jun 4, 2022 | Exploring Mocravimod Key Research Highlights

https://priothera.com/a-two-part-single-and-two-arm-randomized-open-label-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-krp203-in-subjects-with-hematological-malignancies-undergoing-allogeneic-hemat/

Priothera, Adding Quality Years to Life

Get In Touch

Priothera SAS
57 Avenue Général de Gaulle
68300 Saint-Louis, France

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland

© Priothera Ltd. 2025

Priothera SAS
57 Avenue Général de Gaulle
68300 Saint-Louis, France

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland